House Energy & Commerce Committee Chair Frank Pallone (D-NJ) is concerned about efforts to make permanent FDA’s rare pediatric disease priority review voucher (PRV) program. Pallone recently asserted that permanently renewing the program would strain FDA’s resources, coming as a bipartisan group of House lawmakers, including several key E&C members, push for legislation that would permanently reauthorize the program. During a recent E&C health subcommittee hearing, Pallone noted that it seems likely the program will continue in some form, though...